Premium
Resveratrol attenuates bone cancer pain through the inhibition of spinal glial activation and CX 3 CR 1 upregulation
Author(s) -
Cheng Wei,
Zhao Yu,
Liu He,
Fan Qin,
Lu FeiFei,
Li Jing,
Yin Qin,
Yan ChangDong
Publication year - 2014
Publication title -
fundamental and clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.655
H-Index - 73
eISSN - 1472-8206
pISSN - 0767-3981
DOI - 10.1111/fcp.12084
Subject(s) - resveratrol , downregulation and upregulation , bone cancer , spinal cord , chemistry , pharmacology , nociception , medicine , cancer , biochemistry , receptor , psychiatry , gene
The present study examined the effects of intrathecal use of resveratrol on pain hypersensitivities, spinal glia activation, and CX 3 CR 1 expression in the model of bone cancer pain ( BCP ). The BCP model was established through intrathecally injecting W alker 256 mammary gland carcinoma cells to S prague‐ D awley rats. We found that spinal CX 3 CR 1 expression and glial activation aggravated after inoculation. Resveratrol (i.t.) attenuated bone cancer‐induced pain hypersensitivities, decreased CX 3 CR 1 expression and glial activation in the spine in a BCP model. Resveratrol (i.t.) also attenuated mechanical allodynia resulting from intrathecally injecting fractalkine in rats. Inhibition of spinal glial activation and CX 3 CR 1 upregulation may involve in resveratrol's analgesic effects. These findings demonstrated that resveratrol attenuated pain facilitation through inhibiting spinal glial activation and CX 3 CR 1 upregulation in a BCP model.